Silent cerebral infarction in patients with type 2 diabetic nephropathy. Effects of antiplatelet drug dilazep dihydrochloride

Diabetes/Metabolism Research and Reviews

Volumn 21, Issue 1, 2005, Pages 39-43

  Nakamura, Tsukasa ^a   Kawagoe, Yasuhiro ^a   Matsuda, Takaharu ^a   Ueda, Yoshihiko ^b   Ebihara, Isao ^c   Koide, Hikaru ^c  

^a Shinmatsudo Central General Hospital   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c KOTO HOSPITAL   (Japan)

Author keywords

Diabetic nephropathy; Dilazep dihydrochloride; Microalbuminuria; Silent cerebral infarction

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CREATININE; DILAZEP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; BRAIN INFARCTION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE DURATION; DYSLIPIDEMIA; FEMALE; HEMODIALYSIS; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; BRAIN; CEREBRAL INFARCTION; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DILAZEP; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; REFERENCE VALUES; RISK FACTORS; VASODILATOR AGENTS;

EID: 12744263034     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.473     Document Type: Article

References (25)

1. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348: 1215-1222.
2. Fisher CM. Lacunar strokes and infarcts: a review. Neurology 1982; 32: 871-876.
3. Bruno A, Rosenberg GA. The spectrum of lacunar infarction in the elderly. Clin Geriatr Med 1991; 7: 443-453.
4. Nakatani T, Naganuma T, Uchida J, et al. Silent cerebral infarction in hemodialysis patients. Am J Nephrol 2003; 23: 86-90.
5. Shinoda-Tagawa T, Yamasaki Y, Yoshida S, et al. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes. Diabetologia 2002; 45: 188-194.
6. Marzilli M, Trivella MG, Levantesi D, et al. Effect of dilazep on coronary and systemic circulations. Pharmacology 1985; 31: 82-87.
7. Deguchi H, Takeya H, Wada H, et al. Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes. Blood 1997; 90: 2345-2356.
8. Nakamura T, Ushiyama C, Shimada N, et al. Effect of the antiplatelet drug dilazep dihydrochloride on urinary podocytes in patients in the early stage of diabetic nephropathy. Diabetes Care 2000; 23: 1168-1171.
9. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003; 34: 1126-1130.
10. Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S. Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke 1997; 28: 1932-1939.
11. Howard G, Wagenknecht LE, Cai J, Cooper J, Knaut MA, Toole JF. Cigarette smoking and other risk factors for silent cerebral infarction in the general population. Stroke 1998; 29: 913-917.
12. Lee SC, Park SJ, Ki HK, et al. Prevalence and risk factors of silent cerebral infarction in apparently normal adults. Hypertension 2000; 36: 73-77.
13. Kobayashi S, Okada K, Yamashita K. Incidence of silent lacunar lesion in normal adults and its relation to cerebral blood flow and risk factors. Stroke 1991; 22: 1379-1383.
14. Chamorro A, Saiz A, Vila N, et al. Contribution of arterial blood pressure to the clinical expression of lacunar infarction. Stroke 1996; 27: 388-392.
15. Bryan RN, Wells SW, Miller TJ, et al. Infarctlike lesions in the brain: prevalence and anatomic characteristics at MR imaging of the elderly - data from the Cardiovascular Health Study. Radiology 1997; 202: 47-54.
16. Matsui T, Arai H, Yuzuriha T, et al. Elevated plasma homocysteine levels and risk of silent brain infarction in elderly people. Stroke 2001; 32: 1116-1120.
17. Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MMB. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2002; 33: 21-25.
18. Uehara T, Tabuchi M, Mori E. Risk factors for silent cerebral infarcts in subcortical white matter and basal ganglia. Stroke 1999; 30: 378-382.
19. Saitoh T, Daimon M, Eguchi H, et al. Type 2 diabetes is not a risk factor for asymptomatic ischemic brain lesion - the Funagata study. Intern Med 2002; 41: 351-356.
20. Eguchi K, Kario K, Shimada K. Greater impact of coexistence of hypertension and diabetes on silent cerebral infarcts. Stroke 2003; 34: 2471-2474.
21. Nakamura T, Ushiyama C, Takahashi Y, et al. Effect of dilazep dihydrochloride on urinary albumin excretion in patients with autosomal dominant polycystic kidney disease. Nephron 2001; 88 80-82.
22. Yamagishi S, Koga K, Inagaki Y, Amano S, Okamoto T, Takeuchi M. Dilazep hydrochloride, an antiplatelet drug, prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats. Drugs Exp Clin Res 2002; 28: 221-227.
23. Numabe A, Ara N, Hakamada-Taguchi R, et al. Effects of the anti-platelet aggregation drug dilazep on cognitive function in Dahl salt-sensitive rats. Hypertens Res 2003; 26: 185-191.
24. Ebihara I, Nakamura T, Suzuki S, et al. Effect of dilazep dihydrochloride on plasma P-selectin concentrations in patients with IgA nephropathy. Nephron 2000; 85: 281-282.
25. Nakamura T, Ushiyama C, Osada S, et al. Effect of dilazep dihydrochloride on serum cardiac troponin T levels in hemodialysis patients. Kidney Blood Press Res 2002; 25: 50-54.